title: Attenuation of hypertension-mediated glomerulosclerosis in conjunction with increased angiotensin (1-7).
abstract: BACKGROUND
  Controversy exists as to whether angiotensin (1-7) (Ang (1-7)) acts as a protective hormone against renal injury.
  
  
  METHODS
  We compared the degree of improvement of hypertensive nephropathy following 8 weeks' treatment with either the angiotensin II receptor type 1 antagonist olmesartan medoxomil or the cardioselective beta blocker atenolol in 8-week-old spontaneously hypertensive rats (SHRs).
  
  
  RESULTS
  Both treatment regimens reduced mean blood pressure in a similar fashion, while bradycardia was present only in atenolol-treated SHRs. The heart weight:body weight ratio fell more in SHRs medicated with olmesartan versus those receiving atenolol. These changes were associated with increases in plasma Ang II in SHRs given the angiotensin II receptor blocker. At the end of treatment, plasma Ang (1-7) was higher in the olmesartan than atenolol or vehicle groups. The glomerular sclerosis (GS) index was lowered by olmesartan and atenolol compared with the vehicle group. While both olmesartan and atenolol attenuated renal perivascular collagen deposition (PVCD), the greatest effect was observed in SHRs receiving olmesartan. Elevations in plasma Ang (1-7) correlated negatively with reductions in GS or PVCD index, respectively.
  
  
  CONCLUSIONS
  While control of blood pressure remains a critical factor in the prevention of hypertensive nephropathy, Ang (1-7) may play a substantial role in preventing the structural changes in glomerulus through its effect on regulations of blood pressure and renal function.
authors.affiliation: Department of Geriatric Medicine, Ehime University Graduate School of Medicine, Shitsukawa, Toon City, Ehime 791-0295, Japan.
authors.forename: Michiya
authors.initials: M
authors.lastname: Igase
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yokoyama
authors.forename: Carlos M
authors.initials: CM
authors.lastname: Ferrario
mesh_terms: D058671:Adrenergic beta-1 Receptor Antagonists / Q000494:pharmacology* / Q000627:therapeutic use; D000803:Angiotensin I / Q000097:blood / Q000502:physiology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001262:Atenolol / Q000494:pharmacology* / Q000627:therapeutic use; D001794:Blood Pressure / Q000187:drug effects*; D006439:Hemodynamics / Q000187:drug effects; D006973:Hypertension / Q000150:complications; D007093:Imidazoles / Q000494:pharmacology* / Q000627:therapeutic use; D007674:Kidney Diseases / Q000150:complications; D007678:Kidney Glomerulus / Q000187:drug effects / Q000473:pathology; D008297:Male; D000068557:Olmesartan Medoxomil; D010446:Peptide Fragments / Q000097:blood / Q000502:physiology*; D051381:Rats; D011918:Rats, Inbred SHR; D012598:Sclerosis; D013777:Tetrazoles / Q000494:pharmacology* / Q000627:therapeutic use
chemical_list: D058671:Adrenergic beta-1 Receptor Antagonists; D047228:Angiotensin II Type 1 Receptor Blockers; D007093:Imidazoles; D010446:Peptide Fragments; D013777:Tetrazoles; D001262:Atenolol; D000068557:Olmesartan Medoxomil; D000803:Angiotensin I; C118790:angiotensin I (1-7)
references.citation: J Am Soc Nephrol. 2003 May;14(5):1132-44
references.pmid: 12707384
references.citation: Kidney Int. 2008 Mar;73(6):716-23
references.pmid: 18075499
references.citation: Am J Nephrol. 2008;28(4):548-54
references.pmid: 18239381
references.citation: Am J Physiol Renal Physiol. 2010 Jun;298(6):F1297-305
references.pmid: 20375118
references.citation: Hypertension. 2002 Mar 1;39(3):799-802
references.pmid: 11897767
references.citation: Br J Pharmacol. 1994 Jan;111(1):1-3
references.pmid: 8012686
references.citation: Am J Physiol. 1996 Jan;270(1 Pt 2):F141-7
references.pmid: 8769832
references.citation: Am J Physiol Heart Circ Physiol. 2005 Sep;289(3):H1013-9
references.pmid: 15833808
references.citation: Am J Physiol Heart Circ Physiol. 2005 Dec;289(6):H2281-90
references.pmid: 16055515
references.citation: Hypertension. 1995 Jun;25(6):1238-44
references.pmid: 7768568
references.citation: Am J Pathol. 2006 Jun;168(6):1808-20
references.pmid: 16723697
references.citation: Curr Opin Nephrol Hypertens. 2008 May;17(3):266-70
references.pmid: 18408477
references.citation: J Hypertens. 2007 Apr;25(4):871-6
references.pmid: 17351381
references.citation: Hypertension. 2003 Mar;41(3):392-7
references.pmid: 12623933
references.citation: Acta Pharmacol Sin. 2008 Jul;29(7):829-37
references.pmid: 18565281
references.citation: Lab Invest. 1984 Aug;51(2):181-92
references.pmid: 6748613
references.citation: Kidney Int. 2002 Oct;62(4):1349-57
references.pmid: 12234305
references.citation: Kidney Int. 2005 Nov;68(5):2189-96
references.pmid: 16221218
references.citation: Circulation. 2005 May 24;111(20):2605-10
references.pmid: 15897343
references.citation: Curr Opin Nephrol Hypertens. 2008 May;17(3):250-7
references.pmid: 18408475
references.citation: J Am Soc Nephrol. 1994 Oct;5(4):1133-8
references.pmid: 7849254
references.citation: Am J Pathol. 2007 Aug;171(2):438-51
references.pmid: 17600118
references.citation: Adv Pharmacol. 2010;59:197-233
references.pmid: 20933203
references.citation: Am J Hypertens. 2005 Jul;18(7):922-9
references.pmid: 16053988
references.citation: J Cardiovasc Pharmacol. 1996 Jul;28(1):68-74
references.pmid: 8797138